A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects

The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT05110118).